|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM371200717 |
| 003 |
DE-627 |
| 005 |
20250306023431.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240418s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202402580
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1236.xml
|
| 035 |
|
|
|a (DE-627)NLM371200717
|
| 035 |
|
|
|a (NLM)38630978
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Yang, Wei
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Immunogenic Material Vaccine for Cancer Immunotherapy by Structure-Dependent Immune Cell Trafficking and Modulation
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 04.07.2024
|
| 500 |
|
|
|a Date Revised 04.07.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2024 Wiley‐VCH GmbH.
|
| 520 |
|
|
|a Inherently immunogenic materials offer enormous prospects in enhancing vaccine efficacy. However, the understanding and improving material adjuvanticity remain elusive. Herein how the structural presentation of immunopotentiators in a material governs the dynamic dialogue between innate and adaptive immunity for enhanced cancer vaccination is reported. The immunopotentiator manganese into six differing structures that resemble the architectures of two types of pathogens (spherical viruses or rod-like bacteria) is precisely manipulated. The results reveal that innate immune cells accurately sense and respond to the architectures, of which two outperformed material candidates (151 nm hollow spheres and hollow microrods with an aspect ratio of 4.5) show higher competence in creating local proinflammatory environment with promoted innate immune cell influx and stimulation on dendritic cells (DCs). In combination with viral peptides, model proteins, or cell lysate antigens, the outperformed microrod material remarkably primes antigen-specific CD8 cytolytic T cells. In prophylactic and therapeutic regimens, the microrod adjuvanted vaccines display optimal aptitude in tumor suppression in four aggressive murine tumor models, by promoting the infiltration of heterogeneous cytolytic effector cells while decreasing suppressive immunoregulatory populations in tumors. This study demonstrates that a rationally selected architecture of immunogenic materials potentially advances the clinical reality of cancer vaccination
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a cancer immunotherapy
|
| 650 |
|
4 |
|a cancer vaccines
|
| 650 |
|
4 |
|a immune modulation
|
| 650 |
|
4 |
|a material adjuvants
|
| 650 |
|
4 |
|a nanomaterials
|
| 650 |
|
7 |
|a Cancer Vaccines
|2 NLM
|
| 650 |
|
7 |
|a Adjuvants, Immunologic
|2 NLM
|
| 650 |
|
7 |
|a Manganese
|2 NLM
|
| 650 |
|
7 |
|a 42Z2K6ZL8P
|2 NLM
|
| 700 |
1 |
|
|a Cao, Jianwei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Di, Sichen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Wenjin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cheng, Hui
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ren, Hongze
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xie, Yujie
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Liang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yu, Meihua
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Yu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cui, Xingang
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 27 vom: 14. Juli, Seite e2402580
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnas
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:27
|g day:14
|g month:07
|g pages:e2402580
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202402580
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 27
|b 14
|c 07
|h e2402580
|